Renaissance Capital logo

Vigil Neuroscience Priced, Nasdaq: VIGL

Phase 1 biotech developing antibody therapies for neurodegenerative diseases.

Industry: Health Care

Latest Trade: $3.00 0.00 (0.0%)

First Day Return: -9.6%

Return from IPO: -78.6%

Industry: Health Care

We are a microglia-focused company dedicated to improving the lives of patients, caregivers and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates, initially addressing genetically defined patient subpopulations, that we believe will activate and restore microglial function. Our lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In November 2021, the FDA cleared our Investigational New Drug application (IND) for VGL101 in ALSP at doses up to 20 mg/kg. We initiated our first-in-human Phase 1 clinical trial with VGL101 in healthy volunteers in December 2021 and expect to announce topline data in the second half of 2022.
more less
IPO Data
IPO File Date 11/19/2021
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.0
Deal Size ($mm) $98
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/06/2022
Offer Price $14.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.0
Deal Size ($mm) $98
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Jefferies
more
Company Data
Headquarters Cambridge, MA, United States
Founded 2020
Employees at IPO 30
Website www.vigilneuro.com

Vigil Neuroscience (VIGL) Performance